IC‐P‐122: Association Between an Alzheimer's Disease‐Related Hypometabolic Convergence Index in Cognitively Normal Late‐Middle‐Aged People and Three Levels of Genetic Risk for Late‐Onset Alzheimer's Disease
Adam S. Fleisher,Kewei Chen,Napatkamon Ayutyanont,Auttawut Roontiva,Jessica B.S. Langbaum,Wendy Lee,Xiaofen Liu,Dan Bandy,Stephanie Reeder,Gene E. Alexander,Richard J. Caselli,Eric M. Reiman
DOI: https://doi.org/10.1016/j.jalz.2010.05.137
2010-01-01
Abstract:Using fluorodeoxyglucose positron emission tomography (FDG PET) data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), we recently introduced the concept of an AD-related “hypometabolic convergence index”(HCI). And, we demonstrated its potential to predict progression to probable AD in patients with mild cognitive impairment (MCI). The HCI is a voxel-based summary score that reflects the extent to which the pattern and magnitude of hypometabolism in an individual's PET image converges with the pattern and magnitude of hypometabolism in a group of probable AD patients. In this study, we characterized the association between apolipoprotein E (APOE) ∊4 gene dose and the AD-related HCI in late-middle-aged cognitively normal ∊4 homozygotes (HM), heterozygotes (HT), and non-carriers (NC) from our ongoing longitudinal study. Using SPM5, FDG PET scans from 68 participants with AD were compared to 78 elderly healthy controls from the ADNI dataset to establish a regional-to-whole brain z-score map of AD-like hypometabolism. From a separate cohort of 160 cognitively normal individuals age 47-68 (56.68 ± 4.64), including 78 NC, 46 HT, and 36 HM, FDG PET images were compared to the same ADNI healthy control dataset to create comparative hypometabolic maps of each individual subject. HCI, the consistency between the individual hypometabolism maps and the AD-like map, was calculated as the sum of the product of z-scores from each cerebral voxel from these two maps. HCI scores were compared between NC, HT and HM groups. While the HM, HT, and NC groups did not differ significantly in their age, gender, educational level, or neuropsychological test scores, the three groups differed significantly in their HCI's (24.38 ± 4.84, 23.58 ± 3.59, and 21.80 ± 4.09, respectively; ANOVA, p = 0.004). Additionally, there was a significant association between HCI's and APOE ∊4 gene dose (linear trend, p = 0.001). The AD-related HCI in cognitively normal late-middle-aged people is associated with three levels of genetic risk for late-onset AD. This index score offers promise in the pre-symptomatic detection and tracking of AD-associated hypometabolism, assessment of genetic and non-genetic risk factors, and evaluation of promising AD-modifying treatments in pre-symptomatic individuals.